IL304692A - Anti-cd38 antibodies for use in the treatment of antibody-mediated transplant rejection - Google Patents
Anti-cd38 antibodies for use in the treatment of antibody-mediated transplant rejectionInfo
- Publication number
- IL304692A IL304692A IL304692A IL30469223A IL304692A IL 304692 A IL304692 A IL 304692A IL 304692 A IL304692 A IL 304692A IL 30469223 A IL30469223 A IL 30469223A IL 304692 A IL304692 A IL 304692A
- Authority
- IL
- Israel
- Prior art keywords
- antibodies
- antibody
- treatment
- transplant rejection
- mediated transplant
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21159860 | 2021-03-01 | ||
| PCT/EP2022/055080 WO2022184676A1 (en) | 2021-03-01 | 2022-03-01 | Anti-cd38 antibodies for use in the treatment of antibody-mediated transplant rejection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL304692A true IL304692A (en) | 2023-09-01 |
Family
ID=74844778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL304692A IL304692A (en) | 2021-03-01 | 2023-07-24 | Anti-cd38 antibodies for use in the treatment of antibody-mediated transplant rejection |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240228654A9 (enExample) |
| EP (1) | EP4301779A1 (enExample) |
| JP (1) | JP2024507986A (enExample) |
| KR (1) | KR20230154239A (enExample) |
| AU (1) | AU2022230717A1 (enExample) |
| BR (1) | BR112023016352A2 (enExample) |
| CA (1) | CA3209172A1 (enExample) |
| CL (1) | CL2023002495A1 (enExample) |
| IL (1) | IL304692A (enExample) |
| MX (1) | MX2023009868A (enExample) |
| TW (1) | TW202302642A (enExample) |
| WO (1) | WO2022184676A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202545561A (zh) * | 2024-01-16 | 2025-12-01 | 德商莫菲西斯有限責任公司 | 抗體的高度濃縮液體製劑 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020164788A1 (en) | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
| WO1999062526A2 (en) | 1998-06-05 | 1999-12-09 | Mayo Foundation For Medical Education And Research | Use of genetically engineered antibodies to cd38 to treat multiple myeloma |
| US7223397B1 (en) | 1999-01-07 | 2007-05-29 | Research Development Foundation | Potentiation of anti-CD38-Immunotoxin cytotoxicity |
| EP1174440A1 (en) | 2000-07-19 | 2002-01-23 | U-BISys B.V. | A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment |
| KR20140066259A (ko) | 2004-02-06 | 2014-05-30 | 모르포시스 아게 | 항-ｃｄ３８ 인간 항체 및 그의 용도 |
| JP5225069B2 (ja) | 2005-03-23 | 2013-07-03 | ゲンマブ エー／エス | 多発性骨髄腫の治療のためのｃｄ３８に対する抗体 |
| TW200745162A (en) | 2005-05-24 | 2007-12-16 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38 |
| CA2625681C (en) | 2005-10-12 | 2016-08-02 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38 |
| WO2008037257A2 (en) | 2006-09-26 | 2008-04-03 | Genmab A/S | Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| EP2191841A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine |
| EP2191840A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
| EP2191842A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine |
| EP2191843A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| CN107406506A (zh) | 2014-12-04 | 2017-11-28 | 詹森生物科技公司 | 用于治疗急性髓系白血病的抗cd38抗体 |
| EA037548B1 (ru) | 2015-06-24 | 2021-04-12 | Янссен Байотек, Инк. | Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38 |
| US20190233533A1 (en) | 2016-06-28 | 2019-08-01 | Umc Utrecht Holding B.V. | Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38 |
| EP3434692A1 (en) | 2017-07-24 | 2019-01-30 | Encefa | Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases |
| US20220135695A1 (en) * | 2019-03-08 | 2022-05-05 | Cedars-Sinai Medical Center | Anti-cd38 agents for desensitization and treatment of antibody-mediated rejection of organ transplants |
| JP7687956B2 (ja) * | 2019-03-15 | 2025-06-03 | モルフォシス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 自己抗体介在性自己免疫疾患の処置のための、抗ｃｄ３８抗体及びその医薬組成物 |
-
2022
- 2022-02-25 TW TW111106934A patent/TW202302642A/zh unknown
- 2022-03-01 JP JP2023552183A patent/JP2024507986A/ja active Pending
- 2022-03-01 EP EP22708941.4A patent/EP4301779A1/en active Pending
- 2022-03-01 US US18/548,477 patent/US20240228654A9/en active Pending
- 2022-03-01 KR KR1020237033840A patent/KR20230154239A/ko active Pending
- 2022-03-01 MX MX2023009868A patent/MX2023009868A/es unknown
- 2022-03-01 AU AU2022230717A patent/AU2022230717A1/en active Pending
- 2022-03-01 BR BR112023016352A patent/BR112023016352A2/pt unknown
- 2022-03-01 CA CA3209172A patent/CA3209172A1/en active Pending
- 2022-03-01 WO PCT/EP2022/055080 patent/WO2022184676A1/en not_active Ceased
-
2023
- 2023-07-24 IL IL304692A patent/IL304692A/en unknown
- 2023-08-23 CL CL2023002495A patent/CL2023002495A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202302642A (zh) | 2023-01-16 |
| JP2024507986A (ja) | 2024-02-21 |
| BR112023016352A2 (pt) | 2023-10-03 |
| WO2022184676A1 (en) | 2022-09-09 |
| MX2023009868A (es) | 2023-08-29 |
| US20240132618A1 (en) | 2024-04-25 |
| CA3209172A1 (en) | 2022-09-09 |
| CL2023002495A1 (es) | 2023-12-29 |
| KR20230154239A (ko) | 2023-11-07 |
| EP4301779A1 (en) | 2024-01-10 |
| AU2022230717A1 (en) | 2023-09-14 |
| US20240228654A9 (en) | 2024-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY205760A (en) | Humanized antibodies against c-kit | |
| IL277828A (en) | Anti-CD40 antibodies for use in the prevention of graft rejection | |
| IL273871A (en) | ANTI-CD38 antibodies and combinations with ANTI-CD3 and ANTI-CD28 antibodies | |
| IL268007A (en) | Anti-TNF antibodies, preparations and methods for the treatment of active psoriatic arthritis | |
| ZA201301232B (en) | Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl | |
| IL268160A (en) | Anti-TNF antibodies, preparations and methods for the treatment of active ankylosing spondylitis | |
| IL311136A (en) | Anti-CD3 antibody for use in the treatment or prevention of cancer and molecules containing the antibody | |
| SMT202500445T1 (it) | Anticorpi anti-pd-1 per l'uso nel trattamento del cancro | |
| IL286343A (en) | Anti-cd38 antibodies and pharmaceutical preparations thereof for the treatment of autoantibody-mediated autoimmune disease | |
| IL267430A (en) | Use of antibodies against sclerostin to treat the disease | |
| IL289842A (en) | Human anti-liv1 antibodies for cancer therapy | |
| IL310024A (en) | Anti-CD38 antibodies, anti-CD3 antibodies, bispecific antibodies and their uses | |
| IL287832A (en) | Methods of administering anti-cd38 antibody to treat multiple myeloma | |
| SG11202109274TA (en) | Immunotherapy for the treatment of cancer | |
| IL304692A (en) | Anti-cd38 antibodies for use in the treatment of antibody-mediated transplant rejection | |
| EP2164500A4 (en) | USE OF ZEBURALIN FOR THE TREATMENT OF AUTOIMMUNIT DISEASES OR FOR IMMUNE REJECTION OF GRAFTS | |
| IL266106A (en) | Monoclonal antibody and method of use for treatment of lupus | |
| IL286337A (en) | Cancer treatment with her2xcd3 bispecific antibodies in combination with anti-her2 mab | |
| ZA201805051B (en) | Egfl6 specific monoclonal antibodies and methods of their use | |
| EP3897718A4 (en) | CLAZAKIZUMAB FOR THE TREATMENT OF CHRONIC ANTIBODY-MEDIATED REJECTION OF ORGAN TRANSPLANT | |
| EP3891237A4 (en) | COMPOSITION AND PROCESS FOR COBALT CMP | |
| EP4213681C0 (de) | Trinkgefäss mit überzug sowie handtasche und haltevorrichtung für trinkgefäss | |
| ZA202108220B (en) | Association of polyclonal antibodies and anti-pd1 or anti-pdl1 antibodies for the treatment of cancer | |
| HK40091622A (en) | Bispecific antibodies for use in treatment of nlrc4-gof inflammasomapathy | |
| HK40036557A (en) | Anti-cd40 antibodies for use in prevention of graft rejection |